GRM1 is Upregulated Through Gene Fusion and Promoter Swapping in Chondromyxoid Fibroma

Overview

Journal Nat Genet

Specialty Genetics

Date 2014 Mar 25

PMID 24658000

Citations 26

Authors

Karolin H Nord

Henrik Lilljebjorn

Francesco Vezzi

Jenny Nilsson

Linda Magnusson

Johnbosco Tayebwa

Danielle de Jong

Judith V M G Bovee

Pancras C W Hogendoorn

Karoly Szuhai

Affiliations

Soon will be listed here.

Abstract

Glutamate receptors are well-known actors in the central and peripheral nervous systems, and altered glutamate signaling is implicated in several neurological and psychiatric disorders. It is increasingly recognized that such receptors may also have a role in tumor growth. Here we provide direct evidence of aberrant glutamate signaling in the development of a locally aggressive bone tumor, chondromyxoid fibroma (CMF). We subjected a series of CMFs to whole-genome mate-pair sequencing and RNA sequencing and found that the glutamate receptor gene GRM1 recombines with several partner genes through promoter swapping and gene fusion events. The GRM1 coding region remains intact, and 18 of 20 CMFs (90%) showed a more than 100-fold and up to 1,400-fold increase in GRM1 expression levels compared to control tissues. Our findings unequivocally demonstrate that direct targeting of GRM1 is a necessary and highly specific driver event for CMF development.

Citing Articles

Giant Chondromyxoid Fibroma Associated With Epileptic Seizures: A Case Report.

Toader C, Radoi M, Glavan L, Covache-Busuioc R, Ilie M, Popa M Cureus. 2024; 16(10):e70950.

PMID: 39429986 PMC: 11488528. DOI: 10.7759/cureus.70950.

Soft Tissue and Bone Tumor Diagnostics: Harnessing the Power of Molecular Techniques.

Cordier F, Ferdinande L, Hoorens A, Van de Vijver K, Van Dorpe J, Creytens D Genes (Basel). 2023; 14(12).

PMID: 38137051 PMC: 10742688. DOI: 10.3390/genes14122229.

A At-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy.

Xie L, Zhang L, Hu K, Hanyu M, Zhang Y, Fujinaga M Cell Rep Med. 2023; 4(4):100960.

PMID: 37003259 PMC: 10140459. DOI: 10.1016/j.xcrm.2023.100960.

Subcutaneous chondromyxoid fibroma with a novel PNISR::GRM1 fusion-report of a primary soft tissue tumour without connection to an underlying bone.

Zupan A, Salapura V, Sekoranja D, Pizem J Virchows Arch. 2023; 482(5):917-921.

PMID: 36810795 PMC: 10156755. DOI: 10.1007/s00428-023-03519-4.

Experimentally Deduced Criteria for Detection of Clinically Relevant Fusion 3' Oncogenes from FFPE Bulk RNA Sequencing Data.

Rabushko E, Sorokin M, Suntsova M, Seryakov A, Kuzmin D, Poddubskaya E Biomedicines. 2022; 10(8).

PMID: 36009413 PMC: 9405289. DOI: 10.3390/biomedicines10081866.

References

Wang L, Hinoi E, Takemori A, Nakamichi N, Yoneda Y . Glutamate inhibits chondral mineralization through apoptotic cell death mediated by retrograde operation of the cystine/glutamate antiporter. J Biol Chem. 2006; 281(34):24553-65. DOI: 10.1074/jbc.M600939200. View

Chenu C, Serre C, Raynal C, Burt-Pichat B, Delmas P . Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone. 1998; 22(4):295-9. DOI: 10.1016/s8756-3282(97)00295-0. View

Martino J, Wall B, Mastrantoni E, Wilimczyk B, La Cava S, Degenhardt K . Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells. Oncogene. 2012; 32(37):4366-76. PMC: 3910169. DOI: 10.1038/onc.2012.471. View

Rossi S, Szuhai K, Ijszenga M, Tanke H, Zanatta L, Sciot R . EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res. 2007; 13(24):7322-8. DOI: 10.1158/1078-0432.CCR-07-1744. View

Ciceroni C, Bonelli M, Mastrantoni E, Niccolini C, Laurenza M, Larocca L . Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death Differ. 2012; 20(3):396-407. PMC: 3569992. DOI: 10.1038/cdd.2012.150. View

Mohajeri A, Tayebwa J, Collin A, Nilsson J, Magnusson L, Vult von Steyern F . Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer. 2013; 52(10):873-86. DOI: 10.1002/gcc.22083. View

Wang L, Hinoi E, Takemori A, Yoneda Y . Release of endogenous glutamate by AMPA receptors expressed in cultured rat costal chondrocytes. Biol Pharm Bull. 2005; 28(6):990-3. DOI: 10.1248/bpb.28.990. View

Willard S, Koochekpour S . Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications. Int J Biol Sci. 2013; 9(7):728-42. PMC: 3753409. DOI: 10.7150/ijbs.6475. View

Romeo S, Bovee J, Grogan S, Taminiau A, Eilers P, Cleton-Jansen A . Chondromyxoid fibroma resembles in vitro chondrogenesis, but differs in expression of signalling molecules. J Pathol. 2005; 206(2):135-42. DOI: 10.1002/path.1782. View

10.

Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg S . TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013; 14(4):R36. PMC: 4053844. DOI: 10.1186/gb-2013-14-4-r36. View

11.

Nord K, Magnusson L, Isaksson M, Nilsson J, Lilljebjorn H, Domanski H . Concomitant deletions of tumor suppressor genes MEN1 and AIP are essential for the pathogenesis of the brown fat tumor hibernoma. Proc Natl Acad Sci U S A. 2010; 107(49):21122-7. PMC: 3000312. DOI: 10.1073/pnas.1013512107. View

12.

Wang L, Hinoi E, Takemori A, Takarada T, Yoneda Y . Abolition of chondral mineralization by group III metabotropic glutamate receptors expressed in rodent cartilage. Br J Pharmacol. 2005; 146(5):732-43. PMC: 1751195. DOI: 10.1038/sj.bjp.0706358. View

13.

Jin Y, Moller E, Nord K, Mandahl N, Vult von Steyern F, Domanski H . Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes. Genes Chromosomes Cancer. 2012; 51(5):510-20. DOI: 10.1002/gcc.21939. View

14.

Mertens F, Moller E, Mandahl N, Picci P, Perez-Atayde A, Samson I . The t(X;6) in subungual exostosis results in transcriptional deregulation of the gene for insulin receptor substrate 4. Int J Cancer. 2010; 128(2):487-91. DOI: 10.1002/ijc.25353. View

15.

Choi K, Chang K, Pickel J, Badger 2nd J, Roche K . Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice. Proc Natl Acad Sci U S A. 2011; 108(37):15219-24. PMC: 3174576. DOI: 10.1073/pnas.1107304108. View

16.

Yasuda T, Nishio J, Sumegi J, Kapels K, Althof P, Sawyer J . Aberrations of 6q13 mapped to the COL12A1 locus in chondromyxoid fibroma. Mod Pathol. 2009; 22(11):1499-506. PMC: 2784180. DOI: 10.1038/modpathol.2009.101. View

17.

Genever P, Skerry T . Regulation of spontaneous glutamate release activity in osteoblastic cells and its role in differentiation and survival: evidence for intrinsic glutamatergic signaling in bone. FASEB J. 2001; 15(9):1586-8. DOI: 10.1096/fj.00-0594fje. View

18.

Scott D, Mungall K, Ben-Neriah S, Rogic S, Morin R, Slack G . TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood. 2012; 119(21):4949-52. PMC: 3367896. DOI: 10.1182/blood-2012-02-414441. View

19.

Leupin O, Kramer I, Collette N, Loots G, Natt F, Kneissel M . Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res. 2007; 22(12):1957-67. PMC: 2882185. DOI: 10.1359/jbmr.070804. View

20.

Savage S, Mirabello L, Wang Z, Gastier-Foster J, Gorlick R, Khanna C . Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet. 2013; 45(7):799-803. PMC: 3910497. DOI: 10.1038/ng.2645. View